Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...

Japan’s Eisai and US biotech Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.

Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.

Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC ...

New Delhi, January 22 (IANS): The Supreme Court on Thursday reserved its order on a public interest litigation (PIL) seeking ...